News

CDA-1 and CDB-1 were co-developed by Medarex and Massachusetts Biologic Laboratories (MBL). Under the terms of the agreement, Merck gains worldwide rights to develop and commercialize CDA-1 and

Abbott will gain access to Huya’s Chinese bioscience network comprising premier companies, universities, government research institutions and bioparks throughout the country. Huya said that it has agreements in

The three purchasers were two existing investors in the company, Venrock Associates (which is affiliated with Anthony Evnin, a director of the company) and New Enterprise Associates (which

Swiss biopharmaceutical company Actelion has reported a net income of CHF102.1m, or CHF0.83 per diluted share, for the first quarter of 2009, compared to CHF44.5m, or CHF0.36 per

Together, the platforms enable researchers to effectively study the entire genome for epigenetic interactions between DNA and DNA-binding proteins to determine regions of the genome that are transcriptionally

QRxPharma, a specialty pharmaceutical company, has successfully completed a Phase III program pilot study comparing the efficacy and safety profile of MoxDuo IR against component doses of morphine

Concurrent with the signing of the agreement, Bradley Somer will serve as Bio-Path’s medical officer and medical liaison for the conduct of the company’s upcoming Phase I clinical

BioAlliance Pharma said that plasmid AMEP displays anti-angiogenic and anti-metastatic properties. Results presented describe the anti-angiogenic and anti-tumoral properties of the plasmid AMEP biotherapy in in vitro and

Peregrine Pharmaceuticals, a biopharmaceutical company, has reported that updated preliminary data from the initial cohort of 21 patients in its Phase II trial evaluating bavituximab in combination with